FDA Advisors See PML Risk With Colitis Drug Vedolizumab

Two FDA advisory panels - the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee - have expressed concern that treatment with vedolizumab , an experimental drug intended for the treatment of ulcerative colitis and Crohn's disease, may cause progressive multifocal leukoenceophalopathy , an ... (more)


More...